SecBot SecBot
6-K ·Filed Jul 14, 2026

AZN

ASTRAZENECA PLC
BULLISH
Impact 7/10
Horizonmonths Processed4mo ago SEC0001654954-26-006637
Notable filing: 6-K
Actionable Insight ▲ Bullish

Zegfrovy adds a differentiated oral EGFR exon 20 inhibitor to AstraZeneca's leading lung cancer franchise, directly competing with amivantamab (J&J) in a meaningful niche. The Phase III data supports first-line expansion. The deal is immediately revenue-neutral but strategically positions AZN for mid-term sales upside. Monitor FDA/regulatory reviews and launch assumptions in upcoming earnings calls.

DirectionBullish
Confidencehigh
Horizonmonths

Drug in focus

AZN drug pipeline →

sunvozertinib

● Neutral Named in this 6-K
Impact
Phase
Approved (China); Phase 3 first-line data filed for approval
Time to market
Already approved in China (the 6-K calls it an "approved asset"); US/EU timeline not yet announced by AstraZeneca
Next catalyst
None dated

What to watchWatch for (1) the China first-line indication decision and (2) any AstraZeneca regulatory submissions for Zegfrovy in the US/EU, plus whether AZN pays out the up-to-$900M milestones to Dizal, milestone payouts signal successful global filings. Treat this as franchise-building context for AZN's lung-cancer portfolio (Tagrisso et al.), not a standalone share-price event: the $600M upfront is tiny relative to AZN's market cap.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$164.50
T+0 close · Jul 14, 2026 · via day close
Latest settled
−2.66%
T+60 · $160.12
Vs SPY
−6.04%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 14 $164.50entry
  2. T+1 · 4mo ago +2.28%α +1.90% · $168.26
  3. T+5 · 4mo ago +0.01%α +1.31% · $164.52
  4. T+20 · 3mo ago −3.50%α −5.99% · $158.75
  5. T+60 · 6w ago −2.66%α −6.04% · $160.12
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca signed an exclusive global license agreement for Zegfrovy (sunvozertinib), an oral EGFR inhibitor for non-small cell lung cancer with exon 20 insertion mutations. AstraZeneca pays Dizal Pharmaceutical an upfront $600 million plus up to $900 million in milestones, plus tiered royalties, adding a complementary approved asset to its lung cancer portfolio with positive Phase III data already filed for first-line use.

Key Facts

  • AstraZeneca licensed worldwide rights to Zegfrovy (sunvozertinib), an oral irreversible EGFR inhibitor for NSCLC with EGFR exon 20 insertion mutations.
  • Upfront payment of $600 million to Dizal, with up to $900 million in development, regulatory, and sales milestones, plus tiered royalties on global sales.
  • Zegfrovy is already approved in the US and China for second-line treatment after platinum-based chemotherapy.
  • Positive WU-KONG28 Phase III data presented at ASCO 2026 and published in NEJM; sNDA for first-line use submitted to FDA and CDE.
  • Breakthrough Therapy Designation granted by both US FDA and China CDE for first-line EGFR exon 20 insertion NSCLC.
  • Transaction expected to close in H2 2026 and does not impact 2026 financial guidance.

Financial Impact

Upfront $600M cash outflow plus milestone potential of $900M for a total deal value up to $1.5B before royalties. Royalties are tiered on global sales but rates not disclosed.

cash flowoperating expenditurerevenue (future product sales)

Risk Factors

  • Execution risk in integrating and commercializing an externally sourced asset
  • Competition from Johnson & Johnson's amivantamab (Rybrevant) in the same exon 20 insertion segment
  • Milestone and royalty payments reduce net margin if sales underperform
  • Regulatory delays or label restrictions for first-line expansion

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-006637
Document: 0001654954-26-006637-index-headers.html0001654954-26-006637
Document: 0001654954-26-006637-index.html0001654954-26-006637
Document: 0001654954-26-006637.txt0001654954-26-006637

Track record

77 reports on AZN

Performance horizon

18 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
  5. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Wed (11h 53m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 14, 2026